Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V) presented
“Mutations in KRAS are present in approximately 30% of lung cancer patients and we have now confirmed a strong correlation with expression of AXL, the target of our CAB- AXL-ADC, Mec-V. Among all 78 patients treated with Mec-V, 58% of those with tumors harboring mKRAS were alive at one year compared to only 23% lacking the mutation,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “The observed and unprecedented one-year survival among such a heavily pretreated NSCLC population suggests that Mec-V may be a promising treatment option for NSCLC patients across all KRAS mutation variants. Based on these findings and previous discussions with the FDA, a randomized trial of Mec-V in patients with treatment-refractory mKRAS NSCLC is planned for initiation in 2025.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.